- Home
- ME vs CRVS Comparison
ME vs CRVS Comparison
Compare ME & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- CRVS
- Stock Information
- Founded
- ME 2006
- CRVS 2014
- Country
- ME United States
- CRVS United States
- Employees
- ME N/A
- CRVS N/A
- Industry
- ME Precision Instruments
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- CRVS Health Care
- Exchange
- ME Nasdaq
- CRVS Nasdaq
- Market Cap
- ME 168.9M
- CRVS 161.4M
- IPO Year
- ME N/A
- CRVS 2016
- Fundamental
- Price
- ME $0.34
- CRVS $5.57
- Analyst Decision
- ME Hold
- CRVS Buy
- Analyst Count
- ME 1
- CRVS 4
- Target Price
- ME $0.47
- CRVS $10.83
- AVG Volume (30 Days)
- ME 2.3M
- CRVS 470.2K
- Earning Date
- ME 11-06-2024
- CRVS 11-05-2024
- Dividend Yield
- ME N/A
- CRVS N/A
- EPS Growth
- ME N/A
- CRVS N/A
- EPS
- ME N/A
- CRVS N/A
- Revenue
- ME $199,188,000.00
- CRVS N/A
- Revenue This Year
- ME $0.05
- CRVS N/A
- Revenue Next Year
- ME $17.98
- CRVS N/A
- P/E Ratio
- ME N/A
- CRVS N/A
- Revenue Growth
- ME N/A
- CRVS N/A
- 52 Week Low
- ME $0.29
- CRVS $1.05
- 52 Week High
- ME $1.09
- CRVS $6.15
- Technical
- Relative Strength Index (RSI)
- ME 52.68
- CRVS 73.60
- Support Level
- ME $0.29
- CRVS $3.90
- Resistance Level
- ME $0.32
- CRVS $4.75
- Average True Range (ATR)
- ME 0.02
- CRVS 0.43
- MACD
- ME 0.01
- CRVS 0.10
- Stochastic Oscillator
- ME 74.71
- CRVS 74.22
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).